Article
Chemistry, Medicinal
Reinier Cardentey Sanchez, Amado Diaz de la Fe, Alejandro Pelaez Suarez, Dayme Grass, Teresa Morgado Vega, Armando Sanchez Canal, Dario Siniscalco, Maria de los Angeles Robinson Agramonte
Summary: Multiple sclerosis is an autoimmune neurodegenerative disease that lacks a curative treatment. The use of interferon beta 1a has shown safety and efficacy in treating relapsing remitting MS patients, with significant reductions in attacks, disability scale scores, and lesions observed.
DRUG DEVELOPMENT RESEARCH
(2021)
Article
Biology
Cristina-Florentina Plesa, Diana Maria Chitimus, Carmen Adella Sirbu, Monica Marilena Tantu, Minerva Claudia Ghinescu, Daniela Anghel, Florentina Ionita-Radu
Summary: This case study describes a particular association between the remission phase of multiple sclerosis and the violent onset of interferon-induced thrombotic thrombocytopenic purpura.
Article
Clinical Neurology
Alessandro Dinoto, Sara Baldini, Maria Elisa Morelli, Fulvio Pasquin, Alessio Bratina, Antonio Bosco, Arianna Sartori, Paolo Manganotti
Summary: Fatigue in multiple sclerosis patients is closely related to autonomic nervous system symptoms, with orthostatic intolerance potentially playing a predominant role, while cognitive impairment seems to be unrelated to autonomic nervous system symptoms.
NEUROLOGICAL SCIENCES
(2021)
Article
Neuroimaging
Shannon Kolind, Shawna Abel, Carolyn Taylor, Roger Tam, Cornelia Laule, David K. B. Li, Hideki Garren, Laura Gaetano, Corrado Bernasconi, David Clayton, Irene Vavasour, Anthony Traboulsee
Summary: Ocrelizumab appears to protect against demyelination in multiple sclerosis patients and may provide a more favorable environment for remyelination.
NEUROIMAGE-CLINICAL
(2022)
Article
Biochemistry & Molecular Biology
Ranjithkumar Rajendran, Vinothkumar Rajendran, Liza Gupta, Kian Shirvanchi, Darja Schunin, Srikanth Karnati, Mario Giraldo-Velasquez, Martin Berghoff
Summary: This study found that short-term treatment with IFN beta-1a can alleviate symptoms during the peak of disease in multiple sclerosis, while the combined application of IFN beta-1a and specific deletion of FGFR1 can reduce symptoms in the chronic phase. These beneficial effects may be caused by the modulation of FGFR1 rather than interferon beta-1a.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Pharmacology & Pharmacy
Yahiya Y. Syed
Summary: Alemtuzumab is an effective treatment option for patients with highly active RRMS, with maintained treatment benefits over up to 9 years. It has an acceptable tolerability profile and convenient treatment regimen.
Article
Clinical Neurology
Daniel Merlo, Jim Stankovich, Claire Bai, Tomas Kalincik, Chao Zhu, Melissa Gresle, Jeannette Lechner-Scott, Trevor Kilpatrick, Michael Barnett, Bruce Taylor, David Darby, Helmut Butzkueven, Anneke Van der Walt
Summary: This study utilized a computerized cognitive battery and latent class mixed models to identify discrete longitudinal reaction time trajectories in patients with relapsing-remitting multiple sclerosis. The findings indicate that a group of participants showed slowing reaction times and were more likely to experience 6-month confirmed disability progression.
Article
Clinical Neurology
Martin Valis, Zbysek Pavelek, Michal Novotny, Blanka Klimova, Jana Sarlakova, Simona Haluskova, Marek Peterka, Ivana Stetkarova, Pavel Stourac, Jan Mares, Pavel Hradilek, Radek Ampapa, Marta Vachova, Eva Recmanova, Eva Meluzinova
Summary: This study analyzed the characteristics and treatment of pediatric patients with multiple sclerosis. The results showed that these patients usually start disease-modifying drug treatment at the age of 15.89, with moderate and mild relapses being common. Moreover, the first-choice treatment is similar to that of adult patients, but low efficacy or lack of tolerance may lead to treatment discontinuation in children.
FRONTIERS IN NEUROLOGY
(2022)
Article
Clinical Neurology
Chantel D. Mayo, Colleen Lacey, Jodie R. Gawryluk
Summary: The study found that females with RRMS reported higher levels of overall depression and somatic depressive symptoms compared to males, while there were no significant differences in cognitive symptoms reported between the two genders. These findings can help inform treatment planning and future studies should investigate symptom changes longitudinally.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2021)
Article
Clinical Neurology
K. van Der Hiele, D. A. M. van Gorp, E. E. A. van Egmond, P. J. Jongen, M. F. Reneman, J. J. L. van Der Klink, E. P. J. Arnoldus, E. A. C. Beenakker, J. J. J. van Eijk, S. T. F. M. Frequin, K. de Gans, G. J. D. Hengstman, E. Hoitsma, O. H. H. Gerlach, W. I. M. Verhagen, M. A. P. Heerings, H. A. M. Middelkoop, L. H. Visser
Summary: Personality traits did not significantly contribute to occupational functioning in individuals with relapsing-remitting multiple sclerosis, but fatigue and emotional issues, particularly depression and anxiety, were identified as major correlates of work participation and difficulty.
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2021)
Article
Clinical Neurology
Anthony T. Reder, Nancy Arndt, Cortnee Roman, Caroline Geremakis, Jason P. Mendoza, Ray Su, Charles Makin, Robin L. Avila, Megan C. Vignos
Summary: In this study, peginterferon beta-1a was found to be associated with lower annualized relapse rates compared to glatiramer acetate or teriflunomide in RRMS patients, while no significant difference in relapse rates was observed when compared to SC IFN beta-1a. Other measured secondary outcomes also did not show significant differences between the treatment cohorts.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2021)
Article
Clinical Neurology
Furkan Bilek, Nilufer Cetisli-Korkmaz, Zubeyde Ercan, Gulnihal Deniz, Caner Feyzi Demir
Summary: This study shows that aerobic exercise can significantly improve depression, fatigue, and irisin serum levels in MS patients. It provides important clues for further research on the effects of irisin serum levels on these symptoms.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Rehabilitation
Jan Kocica, Jan Kolcava, Michaela Sladeckova, Pavel Stourac, Eva Vlckova, Filip Dosbaba, Jitka Kratochvilova, Josef Bednarik
Summary: This study found that long-term physiotherapy is effective in improving gait and balance problems in patients with MS, and it also alleviates fatigue and symptoms of depression.
JOURNAL OF REHABILITATION MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
James G. Harper, Elizabeth N. York, Rozanna Meijboom, Agniete Kampaite, Michael J. Thrippleton, Patrick K. A. Kearns, Maria del C. Valdes Hernandez, Siddharthan Chandran, Adam D. Waldman
Summary: This study aimed to quantify brain microstructural changes in recently diagnosed relapsing-remitting multiple sclerosis (RRMS) patients using T-1 measures, and determine their associations with clinical disability. The results showed that T-1 is sensitive to brain microstructural changes in early RRMS, and prolonged T-1 in lesions and subtle changes in normal-appearing white matter and gray matter structures are associated with disability.
EUROPEAN RADIOLOGY
(2023)
Article
Rehabilitation
Lindsey M. Knowles, Elizabeth C. Esselman, Aaron P. Turner, Kala M. Phillips, Tracy E. Herring, Kevin N. Alschuler, Dawn M. Ehde
Summary: This study investigated depressive symptom severity and suicidal ideation in individuals with progressive multiple sclerosis and relapsing-remitting multiple sclerosis, finding no significant differences between the two groups. Common risk factors for greater depressive symptom severity included younger age, greater disability, and speech and swallowing problems. Screening for and treating depressive disorders in all MS patients is crucial.
ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
(2021)
Article
Clinical Neurology
Claudio Solaro, Rachele Di Giovanni, Erica Grange, Giampaolo Brichetto, Margit Mueller, Andrea Tacchino, Rita Bertoni, Francesco Patti, Angelo Pappalardo, Luca Prosperini, Letizia Castelli, Rosalba Rosato, Davide Cattaneo, Davide Marengo
Summary: The study aims to evaluate the associations between Manual Ability Measure-36 (MAM-36) and objective measures, including the Nine Hole Peg Test (9-HPT), Box and Block Test (BBT), and Hand Grip Strength (HGS) in people with multiple sclerosis (PwMS). The study found small correlations between MAM-36 and these objective measures, with different correlations seen in different subgroups. Combining 9-HPT and HGS can enhance the assessment of upper limb function in daily activities.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Letter
Clinical Neurology
Emanuele D'Amico, Aurora Zanghi, Virginia Manuti, Caterina Allegretta, Antonella Amoruso, Gaetano Serviddio, Carlo Avolio
JOURNAL OF NEUROLOGY
(2023)
Letter
Clinical Neurology
Emilio Portaccio, Maria Pia Amato
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Clinical Neurology
Ibrahima Diouf, Charles B. Malpas, Sifat Sharmin, Izanne Roos, Dana Horakova, Eva Kubala Havrdova, Francesco Patti, Vahid Shaygannejad, Serkan Ozakbas, Guillermo Izquierdo, Sara Eichau, Marco Onofrj, Alessandra Lugaresi, Raed Alroughani, Alexandre Prat, Marc Girard, Pierre Duquette, Murat Terzi, Cavit Boz, Francois Grand'Maison, Sherif Hamdy, Patrizia Sola, Diana Ferraro, Pierre Grammond, Recai Turkoglu, Katherine Buzzard, Olga Skibina, Bassem Yamout, Ayse Altintas, Oliver Gerlach, Vincent van Pesch, Yolanda Blanco, Davide Maimone, Jeannette Lechner-Scott, Roberto Bergamaschi, Rana Karabudak, Gerardo Iuliano, Chris McGuigan, Elisabetta Cartechini, Michael Barnett, Stella Hughes, Maria Jose Sa, Claudio Solaro, Ludwig Kappos, Cristina Ramo-Tello, Edgardo Cristiano, Suzanne Hodgkinson, Daniele Spitaleri, Aysun Soysal, Thor Petersen, Mark Slee, Ernest Butler, Franco Granella, Koen de Gans, Pamela McCombe, Radek Ampapa, Bart Van Wijmeersch, Anneke van der Walt, Helmut Butzkueven, Julie Prevost, L. G. F. Sinnige, Jose Luis Sanchez-Menoyo, Steve Vucic, Guy Laureys, Liesbeth Van Hijfte, Dheeraj Khurana, Richard Macdonell, Riadh Gouider, Tamara Castillo-Trivino, Orla Gray, Eduardo Aguera-Morales, Abdullah Al-Asmi, Cameron Shaw, Norma Deri, Talal Al-Harbi, Yara Fragoso, Tunde Csepany, Angel Perez Sempere, Irene Trevino-Frenk, Jan Schepel, Fraser Moore, Tomas Kalincik
Summary: This study evaluated the impact of patient characteristics on the response to disease-modifying therapy (DMT) in multiple sclerosis (MS). The results showed that patients with relapsing MS who received DMT had a reduced relapse incidence, lower risk of disability worsening, and greater chance of disability improvement. The effectiveness of DMT was influenced by the severity of disability, prior relapse rate, and prior cerebral magnetic resonance imaging activity, but not by age.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Giacomo Boffa, Alessio Signori, Luca Massacesi, Alice Mariottini, Elvira Sbragia, Salvatore Cottone, Maria Pia Amato, Claudio Gasperini, Lucia Moiola, Stefano Meletti, Anna Maria Repice, Vincenzo Brescia Morra, Giuseppe Salemi, Francesco Patti, Massimo Filippi, Giovanna De Luca, Giacomo Lus, Mauro Zaffaroni, Patrizia Sola, Antonella Conte, Riccardo Nistri, Umberto Aguglia, Franco Granella, Simonetta Galgani, Luisa Maria Caniatti, Alessandra Lugaresi, Silvia Romano, Pietro Iaffaldano, Eleonora Cocco, Riccardo Saccardi, Emanuele Angelucci, Maria Trojano, Giovanni Luigi Mancardi, Maria Pia Sormani, Matilde Inglese
Summary: This study compared the effects of autologous hematopoietic stem cell transplantation (AHSCT) with other anti-inflammatory disease-modifying therapies (DMTs) on long-term disability worsening in active secondary progressive multiple sclerosis (SPMS). The results showed that AHSCT was associated with a slower disability progression and a higher likelihood of disability improvement compared to standard immunotherapy.
Article
Clinical Neurology
R. Veldkamp, M. D'hooge, B. M. Sandroff, J. DeLuca, D. Kos, A. Salter, A. Feinstein, M. P. Amato, G. Brichetto, J. Chataway, R. Farrell, N. D. Chiaravalloti, U. Dalgas, M. Filippi, J. Freeman, R. W. Motl, C. Meza, M. Inglese, M. A. Rocca, G. Cutter, P. Feys
Summary: Performing cognitive-motor dual tasks can negatively affect walking performance and cognitive function in individuals with progressive multiple sclerosis and cognitive impairment. This study examined the dual task performance in different disability levels and found that it significantly affected walking performance, with similar effects across disability subgroups.
JOURNAL OF NEUROLOGY
(2023)
Review
Clinical Neurology
Susana Otero-Romero, Christine Lebrun-Frenay, Saul Reyes, Maria Pia Amato, Magda Campins, Mauricio Farez, Massimo Filippi, Yael Hacohen, Bernhard Hemmer, Rosa Juuti, Melinda Magyari, Celia Oreja-Guevara, Aksel Siva, Sandra Vukusic, Mar Tintore
Summary: This study aims to develop an evidence-based vaccination strategy for pwMS who are candidates for disease-modifying therapies. A multidisciplinary working group conducted a systematic literature search and formulated 53 recommendations based on the quality of evidence. The goal of this study is to homogenize immunization practices in pwMS.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Editorial Material
Clinical Neurology
Matilde Inglese, Maria Pia Amato
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Clinical Neurology
Cyrus Daruwalla, Vahid Shaygannejad, Serkan Ozakbas, Eva Kubala Havrdova, Dana Horakova, Raed Alroughani, Cavit Boz, Francesco Patti, Marco Onofrj, Alessandra Lugaresi, Sara Eichau, Marc Girard, Alexandre Prat, Pierre Duquette, Bassem Yamout, Samia J. Khoury, Seyed Aidin Sajedi, Recai Turkoglu, Ayse Altintas, Olga Skibina, Katherine Buzzard, Pierre Grammond, Rana Karabudak, Anneke van der Walt, Helmut Butzkueven, Davide Maimone, Jeannette Lechner-Scott, Aysun Soysal, Nevin John, Julie Prevost, Daniele Spitaleri, Cristina Ramo-Tello, Oliver Gerlach, Gerardo Iuliano, Matteo Foschi, Radek Ampapa, Vincent van Pesch, Michael Barnett, Nevin Shalaby, Marie D'hooghe, Jens Kuhle, Maria Jose Sa, Marzena Fabis-Pedrini, Allan Kermode, Saloua Mrabet, Riadh Gouider, Suzanne Hodgkinson, Guy Laureys, Liesbeth Van Hijfte, Richard Macdonell, Celia Oreja-Guevara, Edgardo Cristiano, Pamela McCombe, Jose Luis Sanchez-Menoyo, Bhim Singhal, Yolanda Blanco, Stella Hughes, Justin Garber, Claudio Solaro, Chris McGuigan, Bruce Taylor, Koen de Gans, Mario Habek, Abdullah Al-Asmi, Simu Mihaela, Tamara Castillo Trivino, Talal Al-Harbi, Juan Ignacio Rojas, Orla Gray, Dheeraj Khurana, Bart Van Wijmeersch, Nikolaos Grigoriadis, Jihad Inshasi, Jiwon Oh, Eduardo Aguera-Morales, Yara Fragoso, Fraser Moore, Cameron Shaw, Seyed Mohammad Baghbanian, Neil Shuey, Barbara Willekens, Todd A. Hardy, Danny Decoo, Angel Perez Sempere, Deborah Field, Ray Wynford-Thomas, Nick G. Cunniffe, Izanne Roos, Charles B. Malpas, Alasdair J. Coles, Tomas Kalincik, J. William L. Brown, MSBase Study Grp
Summary: This study found that early non-disabling relapses in people with RRMS are associated with a higher risk of disability accumulation, which may be mitigated by high-efficacy DMTs. Therefore, treatment decisions should take into account the impact of non-disabling relapses.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Clinical Neurology
Tomas Kalincik, Sifat Sharmin, Izanne Roos, Mark S. Freedman, Harold Atkins, Joachim Burman, Jennifer Massey, Ian Sutton, Barbara Withers, Richard Macdonell, Andrew Grigg, Oivind Torkildsen, Lars Bo, Anne Kristine Lehmann, Eva Kubala Havrdova, Eva Krasulova, Marek Trneny, Tomas Kozak, Anneke van der Walt, Helmut Butzkueven, Pamela McCombe, Olga Skibina, Jeannette Lechner-Scott, Barbara Willekens, Elisabetta Cartechini, Serkan Ozakbas, Raed Alroughani, Jens Kuhle, Francesco Patti, Pierre Duquette, Alessandra Lugaresi, Samia J. Khoury, Mark Slee, Recai Turkoglu, Suzanne Hodgkinson, Nevin John, Davide Maimone, Maria Jose Sa, Vincent van Pesch, Oliver Gerlach, Guy Laureys, Liesbeth Van Hijfte, Rana Karabudak, Daniele Spitaleri, Tunde Csepany, Riadh Gouider, Tamara Castillo-Trivino, Bruce Taylor, Basil Sharrack, John A. Snowden
Summary: This study compared the effectiveness of autologous hematopoietic stem cell transplant (AHSCT) with fingolimod, natalizumab, and ocrelizumab in treating relapsing-remitting multiple sclerosis (MS). The results showed that AHSCT was more effective than fingolimod and natalizumab in preventing relapses and facilitating recovery from disability. AHSCT had similar effectiveness to ocrelizumab.
Article
Clinical Neurology
Susanna Asseyer, Nasrin Asgari, Jeffrey Bennett, Omer Bialer, Yolanda Blanco, Francesca Bosello., Anna Camos-Carreras., Edgar Carnero Contentti., Sara Carta, John Chen, Claudia Chien, Mashina Chomba, Russell C. Dale, Josep Dalmau, Kristina Feldmann, Eoin P. Flanagan, Caroline Froment Tilikete, Carolina Garcia-Alfonso, Joachim Havla, Mark Hellmann, Ho Jin Kim, Philipp Klyscz, Frank Konietschke, Chiara La Morgia, Marco Lana-Peixoto, Maria Isabel Leite, Netta Levin, Michael Levy, Sara Llufriu, Pablo Lopez, Itay Lotan, Alessandra Lugaresi, Romain Marignier, Sara Mariotto, Susan P. Mollan, Cassandra Ocampo, Frederike Cosima Oertel, Maja Olszewska, Jacqueline Palace, Lekha Pandit, Jose Luis Peralta Uribe, Sean Pittock, Sudarshini Ramanathan, Natthapon Rattanathamsakul, Albert Saiz, Sara Samadzadeh, Bernardo Sanchez-Dalmau, Deanna Saylor, Michael Scheel, Tanja Schmitz-Huebsch, Jemal Shifa, Sasitorn Siritho, Pia S. Sperber, Prem S. Subramanian, Alon Tiosano, Adi Vaknin-Dembinsky, Alvaro Jose Mejia Vergara, Adi Wilf-Yarkoni, Luis Alfonso Zarco, Hanna G. Zimmermann, Friedemann Paul, Hadas Stiebel-Kalish
Summary: This is a global study aimed at investigating the effect of early high-dose corticosteroid treatment on optic neuritis. The study will collect various data to evaluate treatment strategies and the accuracy of diagnostic criteria.
FRONTIERS IN NEUROLOGY
(2023)
Article
Clinical Neurology
Serena Caselli, Loredana Sabattini, Davide Cattaneo, Johanna Jonsdottir, Giampaolo Brichetto, Stefania Pozzi, Alessandra Lugaresi, Fabio La Porta
Summary: This study evaluated the measurement characteristics of the BBS in Multiple Sclerosis using Rasch analysis. The results showed that the BBS-MS has good internal construct validity and reliability, making it a suitable tool for assessing balance, particularly in individuals with advanced walking disability.
FRONTIERS IN NEUROLOGY
(2023)
Article
Medicine, General & Internal
Cristiano Scandurra, Laura Rosa, Antonio Carotenuto, Marcello Moccia, Sebastiano Arena, Antonio Ianniello, Agostino Nozzolillo, Mariavittoria Turrini, Lidia Mislin Streito, Gianmarco Abbadessa, Elisabetta Ferraro, Manuela Mattioli, Alessandro Chiodi, Nelson Mauro Maldonato, Simona Bonavita, Marinella Clerico, Cinzia Cordioli, Lucia Moiola, Francesco Patti, Luigi Lavorgna, Massimo Filippi, Giovanna Borriello, Emanuele D'Amico, Carlo Pozzilli, Vincenzo Brescia Morra, Maria Petracca, Roberta Lanzillo
Summary: Despite being a common issue, sexual dysfunction in people with multiple sclerosis (pwMS) is underinvestigated. This study aimed to assess the potential determinants of sexual dysfunction in pwMS by considering its relationship with disease severity, illness perception, and depressive symptoms. The results showed that disease severity indirectly affects sexual dysfunction through illness perception and depressive symptoms. Illness perception plays a more crucial role in sexual dysfunction for pwMS with mild disability. Modulating the effect of illness perception might be a valid approach to mitigate sexual dysfunction symptoms in pwMS.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Clinical Neurology
Bruno Brochet, Alessandra Solari, Jeannette Lechner-Scott, Fredrik Piehl, Dawn Langdon, Raymond Hupperts, Krzysztof Selmaj, Francesco Patti, Luis Brieva, Eva Maria Maida, Nektaria Alexandri, Andrzej Smyk, Axel Nolting, Birgit Keller, Xavier Montalban, Eva Kubala Havrdova
Summary: Cladribine tablet treatment significantly improved the health-related quality of life in people with highly active relapsing multiple sclerosis, with good safety and tolerability.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Clinical Neurology
Clara Grazia Chisari, Joe Guadagno, Peyman Adjamian, Carlos Vila Silvan, Teresa Greco, Makarand Bagul, Francesco Patti
Summary: A significant proportion of patients with multiple sclerosis-associated spasticity experienced a meaningful reduction in spasticity severity after 12 weeks of treatment with nabiximols.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2023)